MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789

NCT03163550 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-12-02

No results posted yet for this study

Summary

This Phase 1 clinical study is a double-blind, randomized, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics (PK), food effect, and drug interaction potential of ACHN-383 and ACHN-789 co-administered orally as separate capsules in healthy subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

ACHN-383

Oral dose

DRUG

ACHN-789

Oral dose

DRUG

Placebo

Oral dose

Sponsors & Collaborators

  • Achaogen, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel J Cloutier, PharmD · Achaogen, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2017-10-15
Completion
2017-10-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163550 on ClinicalTrials.gov